Opinion|Videos|September 30, 2024
Chronic GVHD Treatment Overview: Immunosuppressives, New Agents, and What Patients Need to Know
Panelists discuss how the current treatment landscape for chronic graft-versus-host disease includes a range of immunosuppressive approaches, from traditional corticosteroids and calcineurin inhibitors to newer approved agents like axatilimab, ruxolitinib, belumosudil, ibrutinib, and abatacept, emphasizing key considerations patients should be aware of when undergoing these therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Let's discuss the current treatment landscape for cGVHD, including emerging therapies and their potential impact on patient care.
- Can you provide an overview of the current treatment approaches for cGVHD? Please highlight GVHD management relies on immunosuppressive treatments like corticosteroids, calcineurin inhibitors, and monoclonal antibodies. Several agents have been approved for various GVHD settings, including axatilimab, ruxolitinib, belumosudil, ibrutinib, and abatacept.
- What key things should patients be aware of when receiving therapies?
Advertisement
Related to this article
Interim AYA-NAV data show most navigation components reached young patients with cancer as designed, though full sessions lagged during treatment.
As bispecifics and cell therapies move outpatient, Kate Kennedy, MSN, APRN, says nurses and APPs should focus on education and atypical infections.
A 3-minute video and quick-reference list of October's 7 FDA cancer approvals, with the biomarker and monitoring points nurses need for each.
Oral vitamin C did not slow clonal growth in the phase 2 EVITA trial but was linked to longer survival.
Kathryn Shady, PhD, RN, OCN, discusses research on emotional dissonance and vicarious trauma among hematology/oncology nurses.
Ellery Palanuk, MSN, RN, CN-BN, explains how navigators rely on multidisciplinary teams and tumor boards as breast cancer treatment evolves.
At EONS 2026, a City of Hope nurse practitioner explains how shifting immunotherapy from infusion to injection can free nurse and chair time.
Oncology nurses play a key role guiding patients about AI breast cancer risk assessment tools, dynamic re-testing, and individualized screening plans.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Daraxonrasib and RAS Inhibition: What Oncology Nurses Need to Know
2
Inside an APP-Led Outpatient Clinic for Bispecific Step-Up Dosing
3
AYA Needs Navigation Trial Meets Most Fidelity Targets at Interim Look
4
Childhood Leukemia Treatment Disrupts Work, Finances for Most Families
5